4//SEC Filing
Happel David 4
Accession 0001104659-23-082722
CIK 0001400118other
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 4:15 PM ET
Size
7.9 KB
Accession
0001104659-23-082722
Insider Transaction Report
Form 4
Happel David
DirectorPresident & CEO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−1,011,826→ 0 totalExercise: $7.15Exp: 2032-10-16→ Common Stock (1,011,826 underlying) - Award
Stock Option (Right to Buy)
2023-07-18+1,011,826→ 1,011,826 totalExercise: $7.15Exp: 2032-10-16→ Series A Common Stock (1,011,826 underlying)
Footnotes (2)
- [F1]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- [F2]25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Sagimet Biosciences Inc.
CIK 0001400118
Entity typeother
Related Parties
1- filerCIK 0001623567
Filing Metadata
- Form type
- 4
- Filed
- Jul 19, 8:00 PM ET
- Accepted
- Jul 20, 4:15 PM ET
- Size
- 7.9 KB